In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1857 News Items found
Alicia Gould is a registered dietitian at MSK who specializes in helping people with cancer get the nutrition they need during treatment.
Ask the Expert
5 Tips If You’ve Completely Lost Your Appetite During Cancer Treatment

Get tips from a Memorial Sloan Kettering dietitian if you’ve completely lost your appetite during cancer treatment.
Group of people posing for a photo
Announcement
19 Undergraduates Complete the 2019 Summer Research Program at GSK

Learn about the 19 students who completed the 2019 Summer Undergraduate Research Program (SURP) at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK).
MSK patient receiving chemotherapy
In the Clinic
6 Breakthroughs That Are Changing Chemotherapy for People with Breast Cancer

Discover some of the latest innovations in chemotherapy for breast cancer.
woman against grey background with her head in her hands
Feature
Coping with Shame Related to Cancer

Find out how to handle feelings of self-blame and shame that may accompany a cancer diagnosis.
Physician-scientist Omar Abdel-Wahab in his lab.
In the Lab
Targeting Errors in How Proteins Are Made Is a Promising Approach for Cancer Treatment

MSK studies look at the role of RNA splicing factors in acute myeloid leukemia and melanoma.
JJ Boelens holding large number 8
Q&A
8 Questions with J. J. Boelens: Giving Kids with Cancer a Second Life

Meet Jaap-Jan “J. J.” Boelens, who joined MSK Kids in 2018 as Chief of the Stem Cell Transplantation and Cell Therapy Service.
Blue cells on a black background
In the Lab
Scientists Create the First Human-Tumor-Derived Model for Studying Rectal Cancer

Scientists at Memorial Sloan Kettering have created a model of rectal cancer using human-tumor-derived organoids.
Red blood cells
Finding
Research Points to a Potential New Approach for Treating Anemia

A class of drugs originally developed to treat certain neurological disorders appears to boost the production of red blood cells.
Rihanna sitting in a chair outside
Feature
Getting to the Root of Pediatric Cancers

MSK Kids is leading a major effort to fully deliver on the promise of precision medicine for our youngest patients.
FDA Grants Breakthrough Therapy Designation to Cobimetinib for MEK Inhibition in Histiocytic Neoplasms, Research Led by MSK

Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).